JP2016509222A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509222A5 JP2016509222A5 JP2015556042A JP2015556042A JP2016509222A5 JP 2016509222 A5 JP2016509222 A5 JP 2016509222A5 JP 2015556042 A JP2015556042 A JP 2015556042A JP 2015556042 A JP2015556042 A JP 2015556042A JP 2016509222 A5 JP2016509222 A5 JP 2016509222A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- subject
- biomarkers
- level
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims 24
- 238000000034 method Methods 0.000 claims 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 17
- 208000024172 Cardiovascular disease Diseases 0.000 claims 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 8
- SATGKQGFUDXGAX-MYWFJNCASA-N 7alpha-hydroxy-3-oxo-4-cholestenoic acid Chemical compound C([C@H]1O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)C(O)=O)C)[C@@]1(C)CC2 SATGKQGFUDXGAX-MYWFJNCASA-N 0.000 claims 7
- 239000004471 Glycine Substances 0.000 claims 6
- 206010022489 Insulin Resistance Diseases 0.000 claims 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 6
- YAADMLWHGMUGQL-VOTSOKGWSA-N N-cinnamoylglycine Chemical compound OC(=O)CNC(=O)\C=C\C1=CC=CC=C1 YAADMLWHGMUGQL-VOTSOKGWSA-N 0.000 claims 6
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 claims 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 6
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 6
- 229960003964 deoxycholic acid Drugs 0.000 claims 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 6
- 229960002743 glutamine Drugs 0.000 claims 6
- 229960002449 glycine Drugs 0.000 claims 6
- 229950009829 prasterone sulfate Drugs 0.000 claims 6
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 6
- 229960004441 tyrosine Drugs 0.000 claims 6
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 claims 5
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 claims 5
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 5
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 5
- 229940116269 uric acid Drugs 0.000 claims 5
- JVGVDSSUAVXRDY-UHFFFAOYSA-N 3-(4-hydroxyphenyl)lactic acid Chemical compound OC(=O)C(O)CC1=CC=C(O)C=C1 JVGVDSSUAVXRDY-UHFFFAOYSA-N 0.000 claims 4
- XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 claims 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 4
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 claims 4
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 claims 4
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 4
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 claims 4
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 claims 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 4
- 206010056474 Erythrosis Diseases 0.000 claims 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- JXRLHZCEMXTCBN-DIBGMJQNSA-N [Hyp(3)]-bradykinin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 JXRLHZCEMXTCBN-DIBGMJQNSA-N 0.000 claims 4
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 4
- ONJSZLXSECQROL-UHFFFAOYSA-N alpha-hydroxyhippuric acid Natural products OC(=O)CNC(=O)C1=CC=CC=C1O ONJSZLXSECQROL-UHFFFAOYSA-N 0.000 claims 4
- 150000003278 haem Chemical class 0.000 claims 4
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims 4
- 229960000310 isoleucine Drugs 0.000 claims 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 4
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims 4
- MZPWKJZDOCIALD-UHFFFAOYSA-N pyrocatechol sulfate Chemical compound OC1=CC=CC=C1OS(O)(=O)=O MZPWKJZDOCIALD-UHFFFAOYSA-N 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- 230000001771 impaired effect Effects 0.000 claims 3
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims 3
- IHCPDBBYTYJYIL-QVDQXJPCSA-N (R)-2-methylbutyrylcarnitine Chemical compound CCC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IHCPDBBYTYJYIL-QVDQXJPCSA-N 0.000 claims 2
- IPOLTUVFXFHAHI-WHIOSMTNSA-N (R)-oleoylcarnitine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IPOLTUVFXFHAHI-WHIOSMTNSA-N 0.000 claims 2
- OTSBKHHWSQYEHK-UHFFFAOYSA-N 1,3-dimethyluric acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(=O)N2 OTSBKHHWSQYEHK-UHFFFAOYSA-N 0.000 claims 2
- NOFNCLGCUJJPKU-UHFFFAOYSA-N 1,7-dimethyluric acid Chemical compound N1C(=O)N(C)C(=O)C2=C1NC(=O)N2C NOFNCLGCUJJPKU-UHFFFAOYSA-N 0.000 claims 2
- FGWUDHZVEBFGKS-UHFFFAOYSA-N 1-o-tert-butyl 2-o-methyl azetidine-1,2-dicarboxylate Chemical compound COC(=O)C1CCN1C(=O)OC(C)(C)C FGWUDHZVEBFGKS-UHFFFAOYSA-N 0.000 claims 2
- KDVFRMMRZOCFLS-UHFFFAOYSA-N 2-oxopentanoic acid Chemical compound CCCC(=O)C(O)=O KDVFRMMRZOCFLS-UHFFFAOYSA-N 0.000 claims 2
- YNOWULSFLVIUDH-UHFFFAOYSA-O 3-dehydrocarnitinium Chemical compound C[N+](C)(C)CC(=O)CC(O)=O YNOWULSFLVIUDH-UHFFFAOYSA-O 0.000 claims 2
- HHDDCCUIIUWNGJ-UHFFFAOYSA-N 3-hydroxypyruvic acid Chemical compound OCC(=O)C(O)=O HHDDCCUIIUWNGJ-UHFFFAOYSA-N 0.000 claims 2
- KWNBDPJHEKVDAW-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-(4-methylphenyl)-4-oxobutanoic acid Chemical compound C1=CC(C)=CC=C1C(C(O)=O)CC(=O)C1=CC=C(Cl)C=C1 KWNBDPJHEKVDAW-UHFFFAOYSA-N 0.000 claims 2
- RWKUXQNLWDTSLO-GWQJGLRPSA-N N-hexadecanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC RWKUXQNLWDTSLO-GWQJGLRPSA-N 0.000 claims 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims 2
- VVPRQWTYSNDTEA-LLVKDONJSA-N O-hexanoyl-L-carnitine Chemical compound CCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VVPRQWTYSNDTEA-LLVKDONJSA-N 0.000 claims 2
- UFAHZIUFPNSHSL-UHFFFAOYSA-N O-propanoylcarnitine Chemical compound CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-UHFFFAOYSA-N 0.000 claims 2
- 229960001009 acetylcarnitine Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- ZGRRONMCJIREIE-UHFFFAOYSA-N benzyl n-[1-(4-chlorophenyl)-3-pyrrolidin-1-ylpropyl]-n-methylcarbamate Chemical compound C=1C=CC=CC=1COC(=O)N(C)C(C=1C=CC(Cl)=CC=1)CCN1CCCC1 ZGRRONMCJIREIE-UHFFFAOYSA-N 0.000 claims 2
- 150000002009 diols Chemical class 0.000 claims 2
- 230000004153 glucose metabolism Effects 0.000 claims 2
- 208000018914 glucose metabolism disease Diseases 0.000 claims 2
- 230000002641 glycemic effect Effects 0.000 claims 2
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 claims 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 2
- 229960000367 inositol Drugs 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims 2
- 229940075559 piperine Drugs 0.000 claims 2
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims 2
- 235000019100 piperine Nutrition 0.000 claims 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 2
- 238000007619 statistical method Methods 0.000 claims 2
- BYXCFUMGEBZDDI-UHFFFAOYSA-N trimethyluric acid Natural products CN1C(=O)N(C)C(=O)C2=C1NC(=O)N2C BYXCFUMGEBZDDI-UHFFFAOYSA-N 0.000 claims 2
- 229940075420 xanthine Drugs 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 238000007681 bariatric surgery Methods 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 claims 1
- 235000006694 eating habits Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000007477 logistic regression Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361758924P | 2013-01-31 | 2013-01-31 | |
| US61/758,924 | 2013-01-31 | ||
| PCT/US2014/011759 WO2014120449A1 (en) | 2013-01-31 | 2014-01-16 | Biomarkers related to insulin resistance progression and methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509222A JP2016509222A (ja) | 2016-03-24 |
| JP2016509222A5 true JP2016509222A5 (cg-RX-API-DMAC7.html) | 2017-02-09 |
| JP6404834B2 JP6404834B2 (ja) | 2018-10-17 |
Family
ID=51262841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556042A Active JP6404834B2 (ja) | 2013-01-31 | 2014-01-16 | インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9910047B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2951313B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6404834B2 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2669620T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014120449A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2907525A1 (en) * | 2013-03-28 | 2014-10-02 | Nestec S.A. | Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention |
| CA2917483A1 (en) * | 2013-07-09 | 2015-01-15 | Stemina Biomarker Discovery, Inc. | Biomarkers of autism spectrum disorder |
| SG11201810254UA (en) * | 2016-05-17 | 2018-12-28 | Univ Osaka | Blood sample analysis method and system, for determining diabetes |
| ES2953498T3 (es) | 2016-06-02 | 2023-11-13 | Metabolon Inc | Método de espectrometría de masas para la detección y cuantificación de metabolitos |
| JP7393206B2 (ja) * | 2016-12-19 | 2023-12-06 | メタボロン，インコーポレイテッド | 腎機能代謝産物の検出及び定量化のための質量分析アッセイ方法 |
| WO2018150077A1 (en) * | 2017-02-16 | 2018-08-23 | Afekta Technologies Oy | Betaine biomarkers for nutritional status, nutritional regimen, endogenous metabolism, or risk of cardiovascular or metabolic diseases |
| EP4617668A3 (en) * | 2017-03-31 | 2025-12-24 | Quest Diagnostics Investments LLC | Methods for quantitation of insulin and c-peptide |
| EP3401683A1 (en) * | 2017-05-10 | 2018-11-14 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Diagnosing metabolic disease by the use of a biomarker |
| ES2999269T3 (en) * | 2018-01-17 | 2025-02-25 | Univ Southampton | Methods to predict risk of and to stratify sarcopenia and nad deficiency |
| CN112740045A (zh) * | 2018-09-27 | 2021-04-30 | 雀巢产品有限公司 | 在儿童期和青年期发展成胰岛素抗性的风险的标志物 |
| US11041847B1 (en) | 2019-01-25 | 2021-06-22 | Ixcela, Inc. | Detection and modification of gut microbial population |
| KR102231928B1 (ko) * | 2019-09-19 | 2021-03-26 | 고려대학교 산학협력단 | 비만대사수술 이후 당뇨병 예후 예측용 바이오마커 조성물 |
| CA3177108A1 (en) * | 2020-04-27 | 2021-11-04 | Wayne R. Matson | Detection and modification of gut microbial population |
| CN112149311B (zh) * | 2020-10-12 | 2021-10-26 | 北京中恒利华石油技术研究所 | 一种基于数量规约的非线性多元统计回归测井曲线预测方法 |
| CN112843036A (zh) * | 2021-01-29 | 2021-05-28 | 中国药科大学 | β-羟基丙酮酸在制备人胰岛淀粉样多肽聚集抑制剂中的应用 |
| CN116087485B (zh) * | 2021-11-08 | 2023-10-20 | 中国医学科学院阜外医院 | 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途 |
| CN114324662B (zh) * | 2021-12-30 | 2022-09-16 | 中南大学 | 用于诊断或预防糖尿病的血清生物标志物的应用 |
| WO2023194615A1 (en) * | 2022-04-07 | 2023-10-12 | Need4Health B.V. | Method for determining insulin dosage |
| JP7736971B2 (ja) * | 2022-10-18 | 2025-09-10 | 株式会社オルトメディコ | 糖尿病境界域者のスクリーニング方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001078652A2 (en) | 2000-04-14 | 2001-10-25 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US7329489B2 (en) | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| WO2005094200A2 (en) | 2003-06-20 | 2005-10-13 | University Of Florida | Biomarkers for differentiating between type 2 and type 2 diabetes |
| US7682782B2 (en) | 2004-10-29 | 2010-03-23 | Affymetrix, Inc. | System, method, and product for multiple wavelength detection using single source excitation |
| US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| US8216848B2 (en) * | 2006-03-24 | 2012-07-10 | Metanomics Gmbh | Means and method for diagnosing diabetes |
| MX341954B (es) * | 2007-07-17 | 2016-09-08 | Metabolon Inc | Biomarcadores para prediabetes, enfermedades cardiovasculares y otros transtornos relacionados con sindrome metabolico, y metodos de uso de los mismos. |
| WO2010005982A2 (en) | 2008-07-07 | 2010-01-14 | The General Hospital Corporation | Multiplexed biomarkers of insulin resistance |
| US20110113863A1 (en) * | 2008-07-15 | 2011-05-19 | Metanomics Health Gmbh | Means and methods diagnosing gastric bypass and conditions related thereto |
| JP2012522989A (ja) * | 2009-03-31 | 2012-09-27 | メタボロン インコーポレイテッド | インスリン抵抗性に関連するバイオマーカー、及びそれを使用する方法 |
| US8367418B2 (en) | 2009-10-23 | 2013-02-05 | Therasyn Sensors, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
| JP2013509588A (ja) | 2009-10-29 | 2013-03-14 | テシス バイオサイエンス， インコーポレイテッド | ２型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー |
| US20140303228A1 (en) * | 2011-10-18 | 2014-10-09 | Metabolon, Inc. | Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same |
| EP2776832A4 (en) * | 2011-11-11 | 2015-06-03 | Metabolon Inc | BIOMARKER FOR BUBBLE CANCER AND METHOD FOR ITS USE |
| US20140343865A1 (en) * | 2011-12-09 | 2014-11-20 | Meredith V. Brown | Biomarkers for Kidney Cancer and Methods Using the Same |
-
2014
- 2014-01-16 ES ES14746017.4T patent/ES2669620T3/es active Active
- 2014-01-16 US US14/763,962 patent/US9910047B2/en active Active
- 2014-01-16 EP EP14746017.4A patent/EP2951313B1/en active Active
- 2014-01-16 ES ES17209399T patent/ES2987582T3/es active Active
- 2014-01-16 WO PCT/US2014/011759 patent/WO2014120449A1/en not_active Ceased
- 2014-01-16 JP JP2015556042A patent/JP6404834B2/ja active Active
- 2014-01-16 EP EP17209399.9A patent/EP3321686B1/en active Active
-
2018
- 2018-01-16 US US15/872,373 patent/US20180203021A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509222A5 (cg-RX-API-DMAC7.html) | ||
| Vaes et al. | Changes in physical activity and all-cause mortality in COPD | |
| Hecksteden et al. | Individual response to exercise training-a statistical perspective | |
| Gerritsen et al. | HPA axis genes, and their interaction with childhood maltreatment, are related to cortisol levels and stress-related phenotypes | |
| Nygaard et al. | Irisin in blood increases transiently after single sessions of intense endurance exercise and heavy strength training | |
| ter Horst et al. | Methods for quantifying adipose tissue insulin resistance in overweight/obese humans | |
| Wood et al. | A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains | |
| Henderson et al. | How are physical activity, fitness, and sedentary behavior associated with insulin sensitivity in children? | |
| ES2669620T3 (es) | Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan | |
| JP2016520192A5 (cg-RX-API-DMAC7.html) | ||
| Fernández-Sanjurjo et al. | Circulating microRNA as emerging biomarkers of exercise | |
| Durrer et al. | Differential impact of acute high-intensity exercise on circulating endothelial microparticles and insulin resistance between overweight/obese males and females | |
| Vandoni et al. | Six minute walk distance and reference values in healthy Italian children: A cross-sectional study | |
| JP2018502286A5 (cg-RX-API-DMAC7.html) | ||
| Martin et al. | Ectopic fat accumulation in patients with COPD: an ECLIPSE substudy | |
| Calenic et al. | Detection of volatile malodorous compounds in breath: current analytical techniques and implications in human disease | |
| Alberton et al. | Rating of perceived exertion in maximal incremental tests during head-out water-based aerobic exercises | |
| Niu et al. | The differences in homocysteine level between obstructive sleep apnea patients and controls: a meta-analysis | |
| Smy et al. | Hair cortisol as a novel biomarker of HPA suppression by inhaled corticosteroids in children | |
| Ning et al. | Serum creatinine-and cystatin C-based indices are associated with the risk of subsequent sarcopenia: evidence from the China Health and Retirement Longitudinal study | |
| Scott et al. | The intensity of a resistance exercise session can be quantified by the work rate of exercise | |
| Golec et al. | Relationship between anthropometric and body composition parameters and anti-SARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: A cohort study | |
| Robertson et al. | A glossary for social-to-biological research | |
| Tee et al. | Effects of exercise modality combined with moderate hypoxia on blood glucose regulation in adults with overweight | |
| Sáenz et al. | Obesity as risk factor for lithiasic recurrence |